Company intelligence / Profile preview

SK Biopharmaceuticals

Seongnam-si, Gyeonggi-do, South Koreaskbp.com ↗
Ownership
Public · 326030
Employees
~750
Development stage
Commercial
01

Overview

SK Biopharmaceuticals has successfully developed two FDA-approved drugs—cenobamate for partial-onset seizures in adults (marketed as XCOPRI®) and solriamfetol for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. Cenobamate has been launched in the US through its own sales network—the first Korean biotech to do so—and approved/marketed in Europe via partners. The company’s pipeline spans CNS disorders and oncology with multiple assets at various clinical stages.

Therapeutic areas
OncologyPsychiatryNeurology
Modalities
Small moleculesTargeted protein degradationRadiopharmaceutical therapyCell & gene therapy
Industry
Biotech
02

Drug pipeline

19 assets

cenobamate

Approved

18 more assets in the full pipeline.

03

Partnerships

Jazz Pharmaceuticals (solriamfetol commercialization)Ono Pharmaceutical Co., Ltd. (cenobamate rights Japan)Arvelle Therapeutics International/Ever Pharma/Eurand/Eurand N.V./Eurofarma Laboratórios S.A.ProEn Therapeutics & Korea Institute of Radiological & Medical Sciences for radiotherapeutic research collaborations
04

Financials

Market cap
$4.6B
Total revenue
$522.1M
Enterprise value
$4.3B

Beyond the preview

Go deeper on SK Biopharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SK Biopharmaceuticals.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call